Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,707 across all filing types
Latest filing 2021-06-14 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Q4FY21 Financial Results Earnings Call on 18th June, 2021
Regulatory Filings
2021-06-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification about an upcoming earnings call scheduled for June 18, 2021, to discuss the financial results for the quarter ended March 31, 2021 (Q4FY21). It includes details about the call, dial-in numbers, and contact information but does not contain the actual financial results or substantive financial data. The document length is 2835 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript (CT) announcement or invitation, but since it does not contain the transcript itself, it is an announcement of the earnings call. However, given the options, the closest and most appropriate classification is Call Transcript (CT) because it pertains directly to the earnings call event. Confidence is high due to clear references to the earnings call and financial results discussion.
2021-06-14 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the approval of an Abbreviated New Drug Application (ANDA) by the US FDA for a generic drug product. It is addressed to stock exchanges and is a formal announcement of a regulatory milestone related to product approval and market exclusivity. The document is short (3006 characters) and does not contain financial statements, detailed financial analysis, or management discussion. It is not an earnings release or annual/interim report. It is not a regulatory filing in the sense of compliance documents or certifications, but rather a corporate announcement about product approval and market status. This fits best under the category of Capital/Financing Update (CAP) as it relates to a significant event impacting the company's product portfolio and potential revenue streams, which is typical for such announcements about drug approvals and market exclusivity. Therefore, the appropriate classification is CAP with high confidence.
2021-06-14 English
NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLIS®) in the US market
Regulatory Filings
2021-06-14 English
Copy of Newspaper Publication
Regulatory Filings
2021-06-09 English
Newspaper Publication for Board Meeting
Regulatory Filings
2021-06-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.